KR102170615B1 - 말초 신경의 IgG 자극된 재수초화 - Google Patents

말초 신경의 IgG 자극된 재수초화 Download PDF

Info

Publication number
KR102170615B1
KR102170615B1 KR1020147027130A KR20147027130A KR102170615B1 KR 102170615 B1 KR102170615 B1 KR 102170615B1 KR 1020147027130 A KR1020147027130 A KR 1020147027130A KR 20147027130 A KR20147027130 A KR 20147027130A KR 102170615 B1 KR102170615 B1 KR 102170615B1
Authority
KR
South Korea
Prior art keywords
delete delete
ivig
polyclonal igg
nerve
igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147027130A
Other languages
English (en)
Korean (ko)
Other versions
KR20140134690A (ko
Inventor
패트릭 쿠에리
네베나 체코바
한스-페터 아르퉁
코리나 헤르만
비르기트 마리아 라이페르트
한스-페터 슈바르츠
하르트무트 에를리히
세바스티안 벙크
Original Assignee
박스알타 인코퍼레이티드
박스앨타 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 박스알타 인코퍼레이티드, 박스앨타 게엠베하 filed Critical 박스알타 인코퍼레이티드
Publication of KR20140134690A publication Critical patent/KR20140134690A/ko
Application granted granted Critical
Publication of KR102170615B1 publication Critical patent/KR102170615B1/ko
Assigned to 다케다 야쿠힌 고교 가부시키가이샤 reassignment 다케다 야쿠힌 고교 가부시키가이샤 권리의 전부이전등록 Assignors: 박스알타 인코퍼레이티드, 박스앨타 게엠베하
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
KR1020147027130A 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화 Active KR102170615B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605117P 2012-02-29 2012-02-29
US61/605,117 2012-02-29
PCT/US2013/028350 WO2013130826A2 (en) 2012-02-29 2013-02-28 Igg stimulated remyelination of peripheral nerves

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207030277A Division KR20200126005A (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화

Publications (2)

Publication Number Publication Date
KR20140134690A KR20140134690A (ko) 2014-11-24
KR102170615B1 true KR102170615B1 (ko) 2020-10-28

Family

ID=47884569

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020147027130A Active KR102170615B1 (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화
KR1020207030277A Ceased KR20200126005A (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화
KR1020227011045A Active KR102673154B1 (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020207030277A Ceased KR20200126005A (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화
KR1020227011045A Active KR102673154B1 (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화

Country Status (21)

Country Link
US (5) US8986670B2 (https=)
EP (2) EP3590960B1 (https=)
JP (3) JP6335800B2 (https=)
KR (3) KR102170615B1 (https=)
CN (4) CN107551269A (https=)
AR (2) AR090211A1 (https=)
AU (3) AU2013203088B2 (https=)
BR (1) BR112014021240A2 (https=)
DK (2) DK2820042T3 (https=)
EA (2) EA201892521A1 (https=)
ES (2) ES2755056T3 (https=)
FI (1) FI3590960T3 (https=)
HK (1) HK1248534A1 (https=)
IL (3) IL277103B2 (https=)
MX (2) MX369444B (https=)
NZ (1) NZ629867A (https=)
PL (2) PL2820042T3 (https=)
PT (2) PT3590960T (https=)
SG (1) SG11201405302WA (https=)
TW (3) TWI700297B (https=)
WO (1) WO2013130826A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107551269A (zh) * 2012-02-29 2018-01-09 百深公司 周围神经的IgG刺激髓鞘再生
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11511136B2 (en) 2017-11-17 2022-11-29 The Research Foundation For The State University Of New York Method for treating damaged peripheral nerves using x-ray microbeam irradiation
EP3908256A4 (en) * 2019-01-07 2022-09-21 Mallinckrodt Ard IP Unlimited Company METHOD TO PROMOTE REMYELINATION
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
EP4737584A1 (en) * 2023-06-30 2026-05-06 FUJIFILM Corporation Method for evaluating intercellular interaction of neuroinflammation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (https=) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
AT376367B (de) 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
EP0124506B1 (de) 1983-05-02 1988-08-17 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Inaktivierung von vermehrungsfähigen Krankheitserregern
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
CA2089582A1 (en) * 1990-08-15 1992-02-16 Richard P. Bunge Autotransplantation of schwann cells to promote nervous system repair
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AU6653094A (en) 1992-12-16 1994-07-04 Immuno Aktiengesellschaft Process for preparing a virus-safe biological composition
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
HRP940645A2 (en) 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
IL140155A (en) 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
IL152738A0 (en) * 2000-05-10 2003-06-24 Mayo Foundation Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP2003070465A (ja) * 2001-08-31 2003-03-11 Keio Gijuku シュワン細胞の培養方法
CA2514117A1 (en) 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
CA2557229C (en) 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
SG178744A1 (en) * 2007-02-02 2012-03-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
US7854703B2 (en) 2007-09-25 2010-12-21 Intel Corporation Peripheral neuropathy detection
CA2643496C (en) 2008-11-06 2015-02-03 Michael Fehlings The therapeutic use of igg as a neuroprotective agent
CN102021140B (zh) * 2009-09-18 2013-04-24 上海市第一人民医院 一种分离、纯化许旺细胞的方法
CN107551269A (zh) * 2012-02-29 2018-01-09 百深公司 周围神经的IgG刺激髓鞘再生

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
P12-11 Nerve conduction characteristics of infliximab induced denyelinating neuropathy*
PNAS, Vol. 107, page s11993-11998 (2010)*

Also Published As

Publication number Publication date
BR112014021240A2 (pt) 2018-09-18
US8986670B2 (en) 2015-03-24
IL234303B (en) 2020-09-30
IL277103B1 (en) 2025-03-01
KR20220045087A (ko) 2022-04-12
JP6637934B2 (ja) 2020-01-29
JP2018030856A (ja) 2018-03-01
ES2755056T3 (es) 2020-04-21
PT3590960T (pt) 2023-04-18
US20210300997A1 (en) 2021-09-30
AR090211A1 (es) 2014-10-29
EA201892521A1 (ru) 2019-07-31
JP6335800B2 (ja) 2018-05-30
HK1206035A1 (en) 2015-12-31
US20130224150A1 (en) 2013-08-29
AU2016201137A1 (en) 2016-03-10
SG11201405302WA (en) 2014-09-26
US20150232536A1 (en) 2015-08-20
EP3590960A1 (en) 2020-01-08
IL274512A (en) 2020-06-30
EP2820042A2 (en) 2015-01-07
WO2013130826A3 (en) 2013-12-05
KR20200126005A (ko) 2020-11-05
CN109966488A (zh) 2019-07-05
TW201400502A (zh) 2014-01-01
KR102673154B1 (ko) 2024-06-05
HK1248534A1 (zh) 2018-10-19
PL2820042T3 (pl) 2020-03-31
IL274512B2 (en) 2024-07-01
TWI700297B (zh) 2020-08-01
EP3590960B1 (en) 2023-03-29
PT2820042T (pt) 2019-10-31
KR20140134690A (ko) 2014-11-24
IL274512B1 (en) 2024-03-01
JP6979990B2 (ja) 2021-12-15
CN104302666A (zh) 2015-01-21
CN107551269A (zh) 2018-01-09
NZ629867A (en) 2016-09-30
AU2018200026B2 (en) 2019-12-05
AU2013203088B2 (en) 2015-12-03
JP2020059705A (ja) 2020-04-16
IL277103A (en) 2020-10-29
ES2943585T3 (es) 2023-06-14
EP2820042B1 (en) 2019-07-24
MX2014010387A (es) 2015-09-25
TW201736398A (zh) 2017-10-16
AU2016201137B2 (en) 2017-10-12
MX369444B (es) 2019-11-08
TW201838654A (zh) 2018-11-01
AU2018200026A1 (en) 2018-01-25
WO2013130826A2 (en) 2013-09-06
US20180291087A1 (en) 2018-10-11
JP2015508824A (ja) 2015-03-23
US20200216518A1 (en) 2020-07-09
CN110343171A (zh) 2019-10-18
AR117207A2 (es) 2021-07-21
PL3590960T3 (pl) 2023-07-17
DK3590960T3 (da) 2023-04-24
DK2820042T3 (da) 2019-10-28
TWI632158B (zh) 2018-08-11
AU2013203088A1 (en) 2013-09-19
FI3590960T3 (fi) 2023-04-25
US10494418B2 (en) 2019-12-03
US9834593B2 (en) 2017-12-05
IL277103B2 (en) 2025-07-01
EA032000B1 (ru) 2019-03-29
MX2019012496A (es) 2020-01-20
EA201400966A1 (ru) 2014-12-30

Similar Documents

Publication Publication Date Title
US20210300997A1 (en) IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES
US9775899B2 (en) Treating neurological disorders
HK40018190B (en) Igg stimulated remyelination of peripheral nerves
HK40018190A (en) Igg stimulated remyelination of peripheral nerves
HK1206035B (en) Igg stimulated remyelination of peripheral nerves
Park et al. Intracortical injection of immune checkpoint inhibitor promotes monocyte/macrophage infiltration and restores microglial function and neuronal activity in an AD mouse model
EA040995B1 (ru) Ремиелинизация периферических нервов, стимулированная igg

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140926

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20160422

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180226

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190318

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190924

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190318

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190924

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190520

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180226

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191210

Patent event code: PE09021S01D

PX0701 Decision of registration after re-examination

Patent event date: 20200721

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20191122

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190924

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20190520

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180226

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20201021

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20201021

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20201021

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee